A randomized, double blind, placebo-controlled, multicenter phase II study to evaluate efficacy and safety of roniciclib in subjects with extensive-stage disease small cell lung cancer (SCLC) who are receiving cisplatin + etoposide or carboplatin + etoposide as first-line therapy

Trial Profile

A randomized, double blind, placebo-controlled, multicenter phase II study to evaluate efficacy and safety of roniciclib in subjects with extensive-stage disease small cell lung cancer (SCLC) who are receiving cisplatin + etoposide or carboplatin + etoposide as first-line therapy

Discontinued
Phase of Trial: Phase II

Latest Information Update: 11 Apr 2017

At a glance

  • Drugs Roniciclib (Primary) ; Carboplatin; Cisplatin; Etoposide
  • Indications Small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms CONCEPT-SCLC
  • Sponsors Bayer HealthCare
  • Most Recent Events

    • 11 Apr 2017 This trial has been suspended in Poland as per European Clinical Trials Database record.
    • 11 Oct 2016 Primary endpoint (Progression-free survival) has not been met as per results presented at the 41st European Society for Medical Oncology Congress
    • 11 Oct 2016 Results presented at the 41st European Society for Medical Oncology Congress
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top